Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00945490
Recruitment Status : Completed
First Posted : July 24, 2009
Last Update Posted : March 10, 2017
Sponsor:
Information provided by (Responsible Party):
Nymox Corporation

Brief Summary:
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.

Condition or disease Intervention/treatment Phase
Benign Prostatic Hyperplasia (BPH) Drug: NX-1207 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Study Start Date : May 2009
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NX-1207 Drug: NX-1207
Single intraprostatic injection of 2.5 mg NX-1207

Placebo Comparator: Placebo Drug: Placebo
Single intraprostatic injection of placebo




Primary Outcome Measures :
  1. American Urological Association Symptom Index (AUASI) [ Time Frame: 365 days ]

Secondary Outcome Measures :
  1. American Urological Association Symptom Index (AUASI) [ Time Frame: 90 days ]
  2. American Urological Association Symptom Index (AUASI) [ Time Frame: 180 days ]
  3. American Urological Association Symptom Index (AUASI) [ Time Frame: 270 days ]
  4. Peak urine flow rate (Qmax) [ Time Frame: 365 days ]
  5. Peak urine flow rate (Qmax) [ Time Frame: 90 days ]
  6. Peak urine flow rate (Qmax) [ Time Frame: 180 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide signed informed consent prior to enrolment in the study
  2. AUASI ≥ 15
  3. Prostate Volume ≥ 30 mL ≤ 70 mL
  4. Qmax < 15 mL/sec based on a minimum void of 125 mL
  5. Agree not to use any other approved or experimental BPH or OAB medication anytime during the study

Exclusion Criteria:

  1. History of illness or condition that may interfere with study or endanger subject
  2. Use of prescribed medications that may interfere with study or endanger subject
  3. Presence of a median lobe of the prostate
  4. Previous surgery or MIST for treatment of BPH
  5. Post-void residual urine volume > 200 mL
  6. PSA ≥ 10 ng/mL; prostate cancer must be ruled out (negative biopsy) for PSA ≥ 4 ng/mL
  7. Participation in a study of any investigational drug or device within the previous 90 days
  8. Prostate cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00945490


Locations
Layout table for location information
United States, California
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Laguna Hills, California, United States, 92653
For information concerning this clinical site, please contact Nymox at 800-936-9669.
San Diego, California, United States, 92103
For information concerning this clinical site, please contact Nymox at 800-936-9669.
San Diego, California, United States, 92120
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Tarzana, California, United States, 91356
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Torrance, California, United States, 90505
United States, Colorado
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Denver, Colorado, United States, 80220
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Englewood, Colorado, United States, 80113
United States, Florida
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Aventura, Florida, United States, 33180
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Ocala, Florida, United States, 34474
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Orlando, Florida, United States, 32803
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Sarasota, Florida, United States, 34237
United States, Idaho
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Meridian, Idaho, United States, 83642
United States, Maryland
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Annapolis, Maryland, United States, 21401
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Baltimore, Maryland, United States, 21237
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Glen Burnie, Maryland, United States, 21061
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Towson, Maryland, United States, 21204
United States, Michigan
For information concerning this clinical site, please contact Nymox at 800-936-9669
Grand Rapids, Michigan, United States, 49546
United States, Minnesota
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Sartell, Minnesota, United States, 56377
United States, Mississippi
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Southaven, Mississippi, United States, 38671
United States, Nevada
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Las Vegas, Nevada, United States, 89146
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Las Vegas, Nevada, United States, 89148
United States, New Jersey
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Brick, New Jersey, United States, 08724
United States, New Mexico
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Albuquerque, New Mexico, United States, 87109
United States, New York
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Albany, New York, United States, 12208
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Garden City, New York, United States, 11530
For information concerning this clinical site, please contact Nymox at 800-936-9669.
New York, New York, United States, 10016
United States, North Dakota
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Bismarck, North Dakota, United States, 58501
United States, Oklahoma
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Bryn Mawr, Pennsylvania, United States, 19010
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Sewickley, Pennsylvania, United States, 15143
United States, Tennessee
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Memphis, Tennessee, United States, 38119
United States, Texas
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Houston, Texas, United States, 77024
For information concerning this clinical site, please contact Nymox at 800-936-9669.
McAllen, Texas, United States, 78503
For information concerning this clinical site, please contact Nymox at 800-936-9669.
San Antonio, Texas, United States, 78229
United States, Virginia
For information concerning this clinical site, please contact Nymox at 800-936-9669.
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
Nymox Corporation
Layout table for additonal information
Responsible Party: Nymox Corporation
ClinicalTrials.gov Identifier: NCT00945490    
Other Study ID Numbers: NX02-0018
First Posted: July 24, 2009    Key Record Dates
Last Update Posted: March 10, 2017
Last Verified: March 2017
Keywords provided by Nymox Corporation:
Benign prostatic hyperplasia
BPH
Enlarged prostate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Hyperplasia
Hyperplasia
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male